" class="no-js "lang="en-US"> Generate Life Sciences to be Acquired by CooperCompanies - Medtech Alert
Sunday, September 24, 2023

Generate Life Sciences to be Acquired by CooperCompanies

Generate Life Sciences® announces it has entered into an agreement to be acquired by the publicly held healthcare company, CooperCompanies (NYSE: COO) and become part of CooperSurgical, a recognized global leader in women’s health and fertility solutions.

For over 40 years Generate has been helping to grow and protect healthy families by providing reproductive, newborn stem cell (umbilical cord blood and tissue) and related genetic services.  Bringing together Generate and Cooper will enable additional growth given CooperSurgical’s established network in over 100 countries, providing greater access to Generate’s innovative science that promotes family wellness.

“Generate helps families around the world benefit from its industry-leading services that support clients throughout their reproductive journey, from pre-conception through post-birth,” said Generate CEO, Richard Jennings. “Over the past several years, our company has transformed into a global life sciences organization supporting clients looking to build and protect their families. Our affiliation with GI Partners was the catalyst to accelerate the growth of the company.”

Generate’s suite of products and services complements the current offerings of CooperSurgical in both fertility solutions and labor & delivery. The combined business will provide fertility clinics and healthcare providers with additional options to support their patients during their assisted reproductive technology treatment and beyond.

The transaction is subject to customary closing conditions, including regulatory approval, with closing expected to occur in Cooper’s Fiscal first quarter.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more